FDA Approved: POLIVY — Supplemental Application (Genentech, Inc.)

View source ↗

Summary

FDA approved a supplemental application for POLIVY (polatuzumab vedotin) from Genentech, Inc., updating its labeling and/or approved indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Polivy (polatuzumab vedotin)

Snippet

SUPPL AP for POLIVY (POLATUZUMAB VEDOTIN)